# Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke

Study · id `cardio:ct-nct06242145` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06242145](<https://clinicaltrials.gov/study/NCT06242145>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06242145

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 580 participants.

## Technical summary

Registry record NCT06242145. Randomized; double masking; primary purpose treatment. Start 2023-01-01 (actual); primary completion 2024-07-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 580 participants (enrolled count; ClinicalTrials.gov record NCT06242145, source copy `cardio:ctgov-nct06242145-2024-08-20`, retrieved 2026-10-26)
- Started: 2023-01-01 (actual) (ClinicalTrials.gov record NCT06242145, source copy `cardio:ctgov-nct06242145-2024-08-20`, retrieved 2026-10-26)
- Primary completion: 2024-07-01 (actual) (ClinicalTrials.gov record NCT06242145, source copy `cardio:ctgov-nct06242145-2024-08-20`, retrieved 2026-10-26)
- Completion: 2024-08-01 (actual) (ClinicalTrials.gov record NCT06242145, source copy `cardio:ctgov-nct06242145-2024-08-20`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT06242145, source copy `cardio:ctgov-nct06242145-2024-08-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06242145-2024-08-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke
- Condition: Ischemic Stroke
- Intervention (Drug): Clopidogrel tablet
- Intervention (Drug): Cilostazol 100 MG
- Lead sponsor: Kafrelsheikh University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Kafrelsheikh University (`cardio:org-kafrelsheikh-university`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cilostazole versus clopidogrel in acute large-vessel moderate and moderate-to-severe ischemic stroke: a randomized controlled trial (`cardio:pubmed-40232632`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 536fbc6a459885b71420f45dc015a1dfaaa88fafdaf116b71cce04ed323a72fa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
